Par Pharmaceutical Companies Release: Par Specialty Pharmaceuticals Launches Cortisporin-TC Otic Suspension

CHESTNUT RIDGE, N.Y., May 26, 2015 /PRNewswire/ -- Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., today announced the launch of Cortisporin^®-TC Otic Suspension (colistin sulfate - neomycin sulfate - thonzonium bromide - hydrocortisone acetate otic suspension).  Cortisporin^®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal (otitis externa), caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.  Cortisporin^®-TC Otic Suspension is the only treatment for otitis externa that contains thonzonium bromide, an ingredient that penetrates discharge to allow colistin (polymixin E), neomycin, and hydrocortisone to contact infected tissue. 

"The Par Specialty sales force will build greater awareness of a product that has long been a trusted remedy for outer ear infections, also known as swimmer's ear," said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies, Inc.  "Therefore, the launch of Cortisporin^®-TC has been timed to coincide with the traditional start of summer, Memorial Day weekend." 

Otitis externa is inflammation of the external ear canal, which is the tube between the outer ear and eardrum, and can often be infected.  Otitis externa is often referred to as "swimmer's ear" because repeated exposure to water can make the ear canal more vulnerable to inflammation. 

Cortisporin^®-TC Otic Suspension is supplied in a 10 mL bottle.  A sterilized dropper-cap assembly for use on the bottle of suspension is included in the package. 

Important Information About Cortisporin^®-TC Otic Suspension 

Cortisporin^®-TC Otic Suspension is contraindicated in patients with a hypersensitivity to any of its components, should not be used if a cutaneous viral infection is suspected or known to exist and should be used cautiously in patients with a perforated tympanic membrane.  Neomycin can cause ototoxicity therefore therapy should be limited to 10 consecutive days and occasionally causes skin sensitization.  The safety and effectiveness of Cortisporin-TC in infants below one year of age have not been established. For full prescribing information, visit www.parpharm.com  

About Par Pharmaceutical Companies, Inc. 

Par is a specialty pharmaceutical company that develops, manufactures and markets safe, innovative and cost-effective pharmaceuticals that help improve patient quality of life.  Par Pharmaceutical offers a line of high-barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands.  Par Sterile Products develops, manufactures and markets both branded and generic aseptic injectable pharmaceuticals.  For press release and other company information, visit www.parpharm.com. 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/par-specialty-pharmaceuticals-launches-cortisporin-tc-otic-suspension-300088560.html

SOURCE Par Pharmaceutical Companies